NetraMark's first presentation, " Novel Machine Learning Approach Outperforms Traditional Approaches in Major Depressive Disorder Clinical Trials", demonstrated how NetraAI Sub-Insight Learning ...
Major depressive disorder with seasonal patterns, also known as seasonal affective disorder, causes symptoms similar to ...
Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...
Researchers have revealed neural circuits in the brainstem that are crucially involved in implementing decisions by ...
TORONTO, ON / ACCESS Newswire / March 5, 2025 / NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE:AIAI)(OTCQB:AINMF)(Frankfurt:8TV) a generative AI software leader in clinical trial analytic ...
Researchers have revealed neural circuits in the brainstem that are crucially involved in implementing decisions by ...
JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033.
The therapy joins another VMAT2 inhibitor, NBI-1065890, which is undergoing assessment by the company in Phase I trials.
Genetic predisposition to traits such as depressive affect, neuroticism and insomnia appeared significantly associated with ...
Learn the difference between having unipolar and bipolar depression and what mental health conditions they are categorized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback